Form 4: Regeneron's CEO Leonard Schleifer Sells Shares Under 10b5-1 Plan

Regeneron's CEO, Leonard Schleifer, executed sales of company stock on May 17, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 17, 2024, Leonard S. Schleifer, the Bd. Co-Chair, President & CEO of Regeneron Pharmaceuticals, Inc., sold shares of common stock.
• The sales were executed under a plan intended to comply with Rule 10b5-1(c), which was adopted on February 5, 2024.
• A total of 22,687 shares were sold at a volume-weighted average price ranging from $979.00 to $979.97.
• An additional 143 shares were sold at a volume-weighted average price ranging from $980.01 to $980.20.
• Following the reported transactions, Schleifer directly owns 466,877 shares of common stock.
• Schleifer also indirectly owns 157,552 shares through a 2023 GRAT, 5,932 shares through a 401(k) plan, and 64,985 shares through a trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by executives are a normal part of executive compensation and portfolio management. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any inside information at the time of the sales.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The sale does not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates